LLY Q2 2026 Call: Massive Guidance Hike, Medicare 'Bridge' Launch, and Oral GLP-1 Superiority
Eli Lilly’s Q2 2026 earnings call was defined by a significant upward revision to full-year guidance, underpinned by the explosive growth of Mounjaro and Zepbound. Beyond the headline numbers, management provided critical color on the July 1st launch of the 'Medicare GLP-1 Bridge Program,' which offers a $50/month out-of-pocket option for 20 million eligible seniors. Investors were particularly focused on the competitive positioning of Orforglipron (oral GLP-1), which demonstrated superior weight loss and glycem...
What changed on the call
Incremental information and investor implications beyond the release.
- Guidance Revision
Full-year revenue guidance was raised by $3 billion at the low end and $2 billion at the high end, now targeting $85B-$87B.
This reflects higher-than-anticipated demand and improving supply chain throughput for the incretin portfolio. - Medicare GLP-1 Bridge Program
Launched July 1, 2026, providing access to 20 million seniors at a $50/month out-of-pocket cost.
This addresses a major coverage gap in Part D and could significantly accelerate volume growth in the senior demographic. - Orforglipron (Oral GLP-1) Superiority
Phase 3 'ACHIEVE' data showed Orforglipron delivered superior glycemic control and weight reduction versus both 7mg and 14mg oral semaglutide.
Establishes Orforglipron as a potential best-in-class daily oral option, simplifying treatment for patients averse to injections. - Retatrutide Regulatory Pathway
Management is pursuing a BLA (Biologic) pathway for Retatrutide, citing its amino acid count and protein-like structure, despite some ongoing litigation/negotiation with the FDA.
A BLA classification provides longer patent/exclusivity protection compared to a small molecule designation.
Guidance and model clarifications
Analyst Q&A
Net Pricing and Formulary Access
Evercore, J.P. MorganCFO Lucas Montarce noted that while CVS/Caremark moved to a different formulary structure, Lilly is focused on 'open access' and expects volume growth to more than offset pricing concessions.
Investor read-through: Net price per prescription may trend lower as more commercial and Medicare volume shifts to rebated channels, but the volume ceiling remains high.
Oral GLP-1 Launch Trajectory
Goldman Sachs, Morgan StanleyIlya Yuffa noted that Orforglipron is seeing an 'inflection point' in July, with new patient starts reaching 1 in 4 for the oral category.
Investor read-through: The oral market is expanding the total addressable market (TAM) rather than just cannibalizing injectables.
Risks and watch items
- Generic Semaglutide Competition
Analysts questioned the impact of generic semaglutide in India and Brazil. Management argued Lilly's 'superiority data' and brand trust are the primary lines of defense.
- Supply Constraints
While guidance was raised, management admitted supply is still 'gating' some international launches, with a full global rollout not expected until 2027.
Management tone
- Manufacturing Capacity
CEO Dave Ricks highlighted the opening of the first dedicated genetic medicine facility in Indiana and the first commercial batch from the new Limerick, Ireland site.
Aggressive and confident. - International Expansion
Management noted strong early uptake in the UAE and Saudi Arabia, emphasizing that international markets are currently primarily out-of-pocket.
Opportunistic but disciplined.
Reinforced on the call
- Alzheimer's Momentum
Kisunla (donanemab) diagnostic testing is doubling YoY, with P-tau217 blood tests becoming a key driver for patient identification.
- M&A Strategy
Recent acquisitions in psychiatry (Atai) and vaccines (Curevo, Limetec) signal a diversification beyond the core metabolic business.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Earnings call webcastFollow LLY in real time
Get material earnings, filing, IR, and earnings-call alerts by email.